Literature DB >> 14638809

The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate.

Thomas A Russo1, Catherine D McFadden, Ulrike B Carlino-MacDonald, Janet M Beanan, Ruth Olson, Gregory E Wilding.   

Abstract

It would be medically and economically desirable to prevent the millions of annual extraintestinal infections and the thousands of associated deaths due to Escherichia coli. Outer membrane proteins are potential vaccine candidates for the prevention of these infections. This study tested the hypotheses that the siderophore receptor IroN is antigenic and that an IroN-specific antibody response confers protection in vivo. Subcutaneous immunization with denatured IroN resulted in a significant IroN immunoglobulin G (IgG)-specific response in serum (P < 0.0001) but not a systemic or mucosal IroN-specific IgA response. In a mouse model of ascending urinary tract infection, subcutaneous immunization with denatured IroN conferred significant protection against renal (P = 0.0135 and 0.0095 in two independent experiments), but not bladder, infection. These data, together with the previously demonstrated role of IroN in virulence, its expression in human biologic fluids, and its prevalence among extraintestinal pathogenic E. coli strains, support further studies on the role of IroN as a vaccine candidate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638809      PMCID: PMC308914          DOI: 10.1128/IAI.71.12.7164-7169.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC.

Authors:  T A Russo; J R Johnson
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

Review 2.  Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.

Authors:  K Gupta; T M Hooton; W E Stamm
Journal:  Ann Intern Med       Date:  2001-07-03       Impact factor: 25.391

3.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

4.  Phylogenetic distribution of extraintestinal virulence-associated traits in Escherichia coli.

Authors:  J R Johnson; P Delavari; M Kuskowski; A L Stell
Journal:  J Infect Dis       Date:  2000-11-22       Impact factor: 5.226

5.  Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial.

Authors:  D A Talan; W E Stamm; T M Hooton; G J Moran; T Burke; A Iravani; J Reuning-Scherer; D A Church
Journal:  JAMA       Date:  2000 Mar 22-29       Impact factor: 56.272

6.  Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.

Authors:  S Langermann; R Möllby; J E Burlein; S R Palaszynski; C G Auguste; A DeFusco; R Strouse; M A Schenerman; S J Hultgren; J S Pinkner; J Winberg; L Guldevall; M Söderhäll; K Ishikawa; S Normark; S Koenig
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

7.  Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients.

Authors:  A C Fluit; F J Schmitz; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-03       Impact factor: 3.267

8.  Increasing rates of hospitalization due to septicemia in the US elderly population, 1986-1997.

Authors:  M McBean; S Rajamani
Journal:  J Infect Dis       Date:  2001-01-17       Impact factor: 5.226

9.  Molecular epidemiological and phylogenetic associations of two novel putative virulence genes, iha and iroN(E. coli), among Escherichia coli isolates from patients with urosepsis.

Authors:  J R Johnson; T A Russo; P I Tarr; U Carlino; S S Bilge; J C Vary; A L Stell
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

10.  Capsular polysaccharide and O-specific antigen divergently modulate pulmonary neutrophil influx in an Escherichia coli model of gram-negative pneumonitis in rats.

Authors:  T A Russo; B A Davidson; R L Priore; U B Carlino; J D Helinski; P R Knight
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

View more
  33 in total

1.  A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Stacy A Genagon; Ulrike MacDonald; John J Cope; Bruce A Davidson; Brian Johnston; James R Johnson
Journal:  Vaccine       Date:  2007-02-05       Impact factor: 3.641

2.  The salmochelin siderophore receptor IroN contributes to invasion of urothelial cells by extraintestinal pathogenic Escherichia coli in vitro.

Authors:  Friederike Feldmann; Liisa Johanna Sorsa; Kirsten Hildinger; Sören Schubert
Journal:  Infect Immun       Date:  2007-03-12       Impact factor: 3.441

3.  Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli.

Authors:  Danilo Gomes Moriel; Isabella Bertoldi; Angela Spagnuolo; Sara Marchi; Roberto Rosini; Barbara Nesta; Ilaria Pastorello; Vanja A Mariani Corea; Giulia Torricelli; Elena Cartocci; Silvana Savino; Maria Scarselli; Ulrich Dobrindt; Jörg Hacker; Hervé Tettelin; Luke J Tallon; Steven Sullivan; Lothar H Wieler; Christa Ewers; Derek Pickard; Gordon Dougan; Maria Rita Fontana; Rino Rappuoli; Mariagrazia Pizza; Laura Serino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

4.  Pathophysiology of Escherichia coli ventilator-associated pneumonia: implication of highly virulent extraintestinal pathogenic strains.

Authors:  Jonathan Messika; Fatma Magdoud; Olivier Clermont; Dimitri Margetis; Stéphane Gaudry; Damien Roux; Catherine Branger; Didier Dreyfuss; Erick Denamur; Jean-Damien Ricard
Journal:  Intensive Care Med       Date:  2012-09-28       Impact factor: 17.440

5.  Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli.

Authors:  Lionel Durant; Arnaud Metais; Coralie Soulama-Mouze; Jean-Marie Genevard; Xavier Nassif; Sonia Escaich
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

6.  α-Intercalated cells defend the urinary system from bacterial infection.

Authors:  Neal Paragas; Ritwij Kulkarni; Max Werth; Kai M Schmidt-Ott; Catherine Forster; Rong Deng; Qingyin Zhang; Eugenia Singer; Alexander D Klose; Tian Huai Shen; Kevin P Francis; Sunetra Ray; Soundarapandian Vijayakumar; Samuel Seward; Mary E Bovino; Katherine Xu; Yared Takabe; Fábio E Amaral; Sumit Mohan; Rebecca Wax; Kaitlyn Corbin; Simone Sanna-Cherchi; Kiyoshi Mori; Lynne Johnson; Thomas Nickolas; Vivette D'Agati; Chyuan-Sheng Lin; Andong Qiu; Qais Al-Awqati; Adam J Ratner; Jonathan Barasch
Journal:  J Clin Invest       Date:  2014-06-17       Impact factor: 14.808

Review 7.  Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis.

Authors:  S M Jacobsen; D J Stickler; H L T Mobley; M E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 8.  The battle for iron between bacterial pathogens and their vertebrate hosts.

Authors:  Eric P Skaar
Journal:  PLoS Pathog       Date:  2010-08-12       Impact factor: 6.823

9.  Outer membrane antigens of the uropathogen Proteus mirabilis recognized by the humoral response during experimental murine urinary tract infection.

Authors:  Greta R Nielubowicz; Sara N Smith; Harry L T Mobley
Journal:  Infect Immun       Date:  2008-07-14       Impact factor: 3.441

10.  Mucosal immunization with iron receptor antigens protects against urinary tract infection.

Authors:  Christopher J Alteri; Erin C Hagan; Kelsey E Sivick; Sara N Smith; Harry L T Mobley
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.